MedPath

Lundbeck Canada Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 3:1
Phase 4:1

Drug Approvals

52

CANADA:26

Drug Approvals

VYEPTI

Approval Date
Jul 1, 2024
CANADA

VYEPTI

Approval Date
Aug 17, 2022
CANADA

TRINTELLIX

Approval Date
Oct 28, 2014
CANADA

TRINTELLIX

Approval Date
Oct 28, 2014
CANADA

TRINTELLIX

Approval Date
Oct 28, 2014
CANADA

CIPRALEX MELTZ

Approval Date
Oct 4, 2012
CANADA

CIPRALEX MELTZ

Approval Date
Oct 4, 2012
CANADA

CIPRALEX -20MG

Approval Date
Feb 14, 2005
CANADA

CIPRALEX -10MG

Approval Date
Feb 14, 2005
CANADA

EBIXA

Approval Date
Dec 16, 2004
CANADA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (50.0%)
Phase 4
1 (50.0%)

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2015-01-07
Last Posted Date
2018-01-30
Lead Sponsor
Lundbeck Canada Inc.
Target Recruit Count
226
Registration Number
NCT02332954
Locations
🇨🇦

CA004, Edmonton, Alberta, Canada

🇨🇦

CA005, Kelowna, British Columbia, Canada

🇨🇦

CA006, St. John's, Newfoundland and Labrador, Canada

and more 23 locations

Real Life Assessment of Abilify Maintena

Terminated
Conditions
Schizophrenia
First Posted Date
2014-05-06
Last Posted Date
2017-03-10
Lead Sponsor
Lundbeck Canada Inc.
Target Recruit Count
200
Registration Number
NCT02131415
Locations
🇨🇦

CA012, Calgary, Alberta, Canada

🇨🇦

CA008, Penticton, British Columbia, Canada

🇨🇦

CA017, Vancouver, British Columbia, Canada

and more 14 locations

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

Phase 3
Completed
Conditions
Indolent Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2011-12-26
Last Posted Date
2017-08-14
Lead Sponsor
Lundbeck Canada Inc.
Target Recruit Count
90
Registration Number
NCT01500083
Locations
🇨🇦

CA015, Calgary, Alberta, Canada

🇨🇦

CA014, Edmonton, Alberta, Canada

🇨🇦

CA016, Kelowna, British Columbia, Canada

and more 13 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.